From: Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans
Type of data | Disease | G-CSF schedules | Chemotherapy | References |
---|---|---|---|---|
Phase I studies with Filgrastim | none | single application 3, 5, 10 μ g/kg | none | [31] |
none | single application 5, 10 μ g/kg | none | [60] | |
 | none | 10 applications 75, 150, 300, 600 μ g | none | [61] |
 | none | 14 applications 30, 300 μ g | none | [62] |
 | none | single application 4, 8 μ g/kg | none | [63] |
Phase I studies with Pegfilgrastim | none | 30, 60, 100, 300 μ g/kg | none | [50] |
Phase II studies with Pegfilgrastim | LuCa | 30, 100, 300 μ g/kg | none | [64] |
 | NHL | 6000 μ g, day 2 | CHOP | [65] |
Phase III studies with CX and w/wo Filgrastim | NHL | no G-CSF | CHOP-21* | [12] |
NHL | 480 μ g, day 4–13 | CHOP-14* | [12] | |
NHL | 480 μ g, day 6–12 | CHOP-14* | [66] | |
Phase III studies with CX + Peg | NHL | 6000 μ g, day 2, 4 | CHOP-14* | [67] |